CY1111292T1 - MULTI-PHASE PREPARATION FOR NATURAL OSTROGEN ON CONTRACTION - Google Patents

MULTI-PHASE PREPARATION FOR NATURAL OSTROGEN ON CONTRACTION

Info

Publication number
CY1111292T1
CY1111292T1 CY20101100913T CY101100913T CY1111292T1 CY 1111292 T1 CY1111292 T1 CY 1111292T1 CY 20101100913 T CY20101100913 T CY 20101100913T CY 101100913 T CY101100913 T CY 101100913T CY 1111292 T1 CY1111292 T1 CY 1111292T1
Authority
CY
Cyprus
Prior art keywords
natural
ostrogen
contraction
phase preparation
ovulatory
Prior art date
Application number
CY20101100913T
Other languages
Greek (el)
Inventor
Jan Endrikat
Bernd Düsterberg
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111292(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of CY1111292T1 publication Critical patent/CY1111292T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

Η εφεύρεση αναφέρεται σε παρασκεύασμα πολλαπλών φάσεων για αντισύλληψη βασιζόμενο σε φυσικό οιστρογόνο σε συνδυασμό με συνθετικό γεσταγόνο, το οποίο σε σύγκριση με συνήθη αντι-ωορρηκτικά παρασκευάσματα της κατηγορίας αυτής, τα οποία από παλιά έχουν αποδειχθεί αξιόπιστα και ασφαλή για ευρεία χρήση, επιτυγχάνει για όλη τη διάρκεια του κύκλου υψηλότερη αντισυλληπτική ασφάλεια, βελτιώνει την κυκλική συμπεριφορά αιμορραγίας και ελαχιστοποιεί τις παρενέργειες, όπως τάσεις στο στήθος, πονοκεφάλους, καταθλιπτική διάθεση και αλλαγές γενετήσιας ορμής κ.ο. ή τις αποκλείει.The invention relates to a multi-stage formulation for natural estrogen-based contraception in combination with synthetic gestagen, which in comparison with conventional anti-ovulatory preparations of this class, which has long been proven reliable and safe for widespread use, achieves all longer cycle contraceptive safety, improves circular bleeding behavior and minimizes side effects, such as chest tendencies, headaches, depressive mood and sex changes. As momentum volume or excludes them.

CY20101100913T 2004-04-20 2010-10-14 MULTI-PHASE PREPARATION FOR NATURAL OSTROGEN ON CONTRACTION CY1111292T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004019743A DE102004019743B4 (en) 2004-04-20 2004-04-20 Multiphase preparation for contraception based on natural estrogen
EP05730867.8A EP1740163B2 (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen

Publications (1)

Publication Number Publication Date
CY1111292T1 true CY1111292T1 (en) 2015-08-05

Family

ID=34979546

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100913T CY1111292T1 (en) 2004-04-20 2010-10-14 MULTI-PHASE PREPARATION FOR NATURAL OSTROGEN ON CONTRACTION

Country Status (38)

Country Link
US (3) US8071577B2 (en)
EP (1) EP1740163B2 (en)
JP (1) JP4908399B2 (en)
KR (1) KR20060134168A (en)
CN (1) CN1946383B (en)
AR (2) AR048830A1 (en)
AT (1) ATE473734T1 (en)
AU (1) AU2005235418C1 (en)
BR (1) BRPI0510005A (en)
CA (1) CA2561839C (en)
CR (1) CR8695A (en)
CY (1) CY1111292T1 (en)
DE (2) DE102004019743B4 (en)
DK (1) DK1740163T4 (en)
EA (1) EA010313B1 (en)
EC (1) ECSP067000A (en)
ES (1) ES2348038T5 (en)
GT (1) GT200500093A (en)
HK (1) HK1099701A1 (en)
HR (1) HRP20100513T4 (en)
IL (2) IL178510A (en)
ME (1) ME01183B (en)
MX (1) MXPA06012213A (en)
MY (1) MY143669A (en)
NO (1) NO344098B1 (en)
NZ (1) NZ550417A (en)
PA (1) PA8630901A1 (en)
PE (1) PE20060308A1 (en)
PL (1) PL1740163T5 (en)
PT (1) PT1740163E (en)
RS (1) RS51434B2 (en)
SI (1) SI1740163T2 (en)
SV (1) SV2006002090A (en)
TW (1) TWI351960B (en)
UA (1) UA83915C2 (en)
UY (1) UY28863A1 (en)
WO (1) WO2005102247A2 (en)
ZA (1) ZA200609594B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
ES2382459T3 (en) * 2005-10-13 2012-06-08 Bayer Pharma Aktiengesellschaft Use of estradiol valerate, in combination with dienogest for oral therapy of dysfunctional uterine bleeding, in conjunction with oral contraception
ES2322479T3 (en) * 2005-10-13 2009-06-22 Bayer Schering Pharma Aktiengesellschaft USE OF ESTRADIOL VALERATE IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY OF DYSFUNCTIONAL UTERINE HEMORRAGY, IN UNION WITH AN ORAL CONTRACEPTION.
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
CA2640520C (en) 2006-03-02 2014-04-22 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
DE102006010329A1 (en) * 2006-03-06 2007-09-13 Höltge, Michael, Dipl.-Med. Hormonal contraceptive, comprises combination preparation of testosterone, gestogen, and esterogen, in the form of single, double or multi-phase preparation
EP1930010A1 (en) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido
US20090117183A1 (en) * 2007-11-05 2009-05-07 Sabine Fricke Oral contraceptive containing a gestagen and an estrogen combined with pharmaceutically acceptable auxiliary agents and/or excipients, but not containing lactose, and method of making same
TW201306825A (en) * 2011-05-11 2013-02-16 Kirax Corp Package for improved treatment of conditions

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4168068A (en) 1969-07-22 1971-01-28 Unisearch Limited Improvements in or relating to oral contraceptives
US3639600A (en) * 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) * 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US4066757A (en) * 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (en) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Use of hormones for contraception
DE2431704A1 (en) 1974-07-02 1976-01-22 Asche Ag Three-stage combination oral contraceptives - contg. oestrogen with increasing doses of gestagen
DE2645307A1 (en) 1976-10-05 1978-04-06 Schering Ag NEW MEANS AND NEW METHODS FOR TREATING CLIMATE FAILURE
JPS6019734B2 (en) 1977-05-12 1985-05-17 三共株式会社 Method for producing stable prostaglandin E preparations
US4272270A (en) 1979-04-04 1981-06-09 Petrochem Consultants, Inc. Cryogenic recovery of liquid hydrocarbons from hydrogen-rich
NL8001593A (en) * 1980-03-18 1981-10-16 Akzo Nv MULTI-PHASIC COMBINATION PREPARATION FOR ORAL ANTI-CONCEPTION.
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (en) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Three-phase product for contraception composed of ethinylestradiol and lynestrenol
DE3347125A1 (en) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION
AU581486B2 (en) 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
CA2005933A1 (en) 1989-01-09 1990-07-09 Jesse Hipps, Sr. Photohardenable composition containing five member aromatic group with imine moiety
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (en) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (en) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
DE4308406C1 (en) 1993-03-12 1994-06-16 Jenapharm Gmbh Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen
DE4313926A1 (en) * 1993-04-28 1994-11-03 Jenapharm Gmbh Multiphase pharmaceutical product for hormonal contraception
DE4339934C2 (en) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Anti-ovulation agent for hormonal contraception
NL9301562A (en) 1993-09-09 1995-04-03 Saturnus Ag Substitution therapy preparation.
DE4344462C2 (en) 1993-12-22 1996-02-01 Schering Ag Composition for contraception
DE4429374C1 (en) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component
DE19525017A1 (en) * 1995-06-28 1997-01-02 Schering Ag Pharmaceutical combination preparation, kit and method for hormonal contraception
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
DE19540253C2 (en) * 1995-10-28 1998-06-04 Jenapharm Gmbh Multi-phase preparation for contraception based on natural estrogens
JP2000515889A (en) * 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション Biphasic contraceptive method and kit comprising a mixture of progestin and estrogen
ATE271386T1 (en) 1996-07-26 2004-08-15 Wyeth Corp ORAL SINGLE STAGE CONTRACEPTION METHOD AND COMBINATION PRODUCT CONTAINING PROGESTEN AND ESTROGEN
CN1119999C (en) 1996-07-26 2003-09-03 惠氏公司 Oral contraceptive
DE19654609A1 (en) * 1996-12-20 1998-06-25 Schering Ag Therapeutic progestogens for the treatment of premenstrual dysphoric disorder
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6312772B1 (en) * 1997-10-20 2001-11-06 Hoechst Celanese Corporation Multilayer laminate formed from a substantially stretched non-molten wholly aromatic liquid crystalline polymer and non-polyester thermoplastic polymer
DE19908762A1 (en) * 1999-02-18 2000-08-31 Jenapharm Gmbh Use of dienogest in high doses
DE10045380A1 (en) 2000-09-14 2002-04-04 Schering Ag Contraception procedure and dosage form
US6699820B2 (en) * 2001-03-02 2004-03-02 Hartmut Ulrich Bielefeldt Method for making a superconductor with enhanced current carrying capability
DE10294402D2 (en) * 2001-09-29 2004-11-11 Solvay Pharm Gmbh Estrogen-progestogen combination preparation and application
EP1462106A1 (en) 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
US20050032758A1 (en) 2003-06-25 2005-02-10 Ina Rudolph Hormone replacement therapy and depression
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
US20060135496A1 (en) * 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
ES2322479T3 (en) 2005-10-13 2009-06-22 Bayer Schering Pharma Aktiengesellschaft USE OF ESTRADIOL VALERATE IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY OF DYSFUNCTIONAL UTERINE HEMORRAGY, IN UNION WITH AN ORAL CONTRACEPTION.
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (en) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido

Also Published As

Publication number Publication date
CA2561839C (en) 2009-09-29
US20110124612A1 (en) 2011-05-26
PL1740163T5 (en) 2020-10-05
CR8695A (en) 2008-07-29
CN1946383A (en) 2007-04-11
AU2005235418C1 (en) 2015-05-21
DE102004019743A1 (en) 2005-11-24
NZ550417A (en) 2010-01-29
RS51434B (en) 2011-04-30
HRP20100513T4 (en) 2020-10-02
DE502005009904D1 (en) 2010-08-26
MY143669A (en) 2011-06-30
ES2348038T5 (en) 2020-09-14
DK1740163T3 (en) 2010-10-18
NO344098B1 (en) 2019-09-02
PA8630901A1 (en) 2006-05-16
PE20060308A1 (en) 2006-05-25
AR084229A2 (en) 2013-05-02
JP2007533681A (en) 2007-11-22
EA200601844A1 (en) 2007-04-27
UY28863A1 (en) 2005-11-30
IL178510A (en) 2015-08-31
NO20065292L (en) 2007-01-17
EP1740163B2 (en) 2020-01-15
HRP20100513T1 (en) 2010-11-30
PT1740163E (en) 2010-09-28
BRPI0510005A (en) 2007-09-18
TWI351960B (en) 2011-11-11
ATE473734T1 (en) 2010-07-15
GT200500093A (en) 2006-04-17
AU2005235418B2 (en) 2009-08-06
WO2005102247A3 (en) 2006-01-12
HK1099701A1 (en) 2007-08-24
IL178510A0 (en) 2007-02-11
DE102004019743B4 (en) 2008-11-27
DK1740163T4 (en) 2020-04-06
US8071577B2 (en) 2011-12-06
SV2006002090A (en) 2006-02-15
RS51434B2 (en) 2020-11-30
AR048830A1 (en) 2006-05-31
KR20060134168A (en) 2006-12-27
ZA200609594B (en) 2008-04-30
US20070259840A1 (en) 2007-11-08
JP4908399B2 (en) 2012-04-04
AU2005235418A1 (en) 2005-11-03
SI1740163T2 (en) 2020-04-30
MXPA06012213A (en) 2007-01-17
ME01183B (en) 2013-03-20
CN1946383B (en) 2010-06-09
TW200534860A (en) 2005-11-01
EP1740163A2 (en) 2007-01-10
UA83915C2 (en) 2008-08-26
ES2348038T3 (en) 2010-11-29
EP1740163B1 (en) 2010-07-14
SI1740163T1 (en) 2010-11-30
US20100173877A1 (en) 2010-07-08
IL239861A0 (en) 2015-08-31
EA010313B1 (en) 2008-08-29
CA2561839A1 (en) 2005-11-03
WO2005102247A2 (en) 2005-11-03
PL1740163T3 (en) 2010-12-31
ECSP067000A (en) 2006-12-29

Similar Documents

Publication Publication Date Title
CY1111292T1 (en) MULTI-PHASE PREPARATION FOR NATURAL OSTROGEN ON CONTRACTION
CY1121215T1 (en) ANTI-VACCINES WITH IMPROVED CELLULAR IMMUNOGENOCITY
CY1122337T1 (en) SULPHAMOYLTHIOPHANAMIDE DERIVATIVES AND THEIR USE AS DRUGS FOR THE THERAPEUTIC TREATMENT OF HEPATITIS B
CY1122372T1 (en) COMPOSITION OF NASAL INFLUENZA VACCINE
CY1118492T1 (en) NOROVIRUS VACCINE PHARMACEUTICAL FORMS
CY1119927T1 (en) CLINIC UNIONS FOR USE IN THERAPEUTIC MEDICINES AND VACCINES
CY1121632T1 (en) RV2386C TUBERCULOSIS PROTEIN, ITS COMPOSITIONS AND USES
CY1110793T1 (en) Tuberculosis Vaccine with Improved Efficiency
CY1117689T1 (en) COMPOSITIONS CONTAINING PULMONARY ANTIGENS
CY1118171T1 (en) THERAPEUTIC TREATMENT OF BEN4
CY1116904T1 (en) VACCINE
CY1122168T1 (en) PHARMACEUTICAL FORMS OF DECITABINE DERIVATIVES
CY1106532T1 (en) HETEROLOGOUS EXPRESSION OF NEISSERIA PROTEINS
CO7170160A2 (en) New 6-amino acid-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CY1123056T1 (en) NEW FORM OF ADMINISTRATION OF RACECADOTRIL
DK1635863T3 (en) Compositions for triggering, enhancing and maintaining immune responses to MHC class-I restricted epitopes for prophylactic or therapeutic purposes
CY1113738T1 (en) Vaccines Against Low-Influenza Influenza In Additives
CY1125338T1 (en) LIPOCATION DENDRIMERS AND USES THEREOF
BRPI0508064A (en) flavivirus, vaccine composition and nucleic acid molecule
CR10732A (en) USE OF ESTRADIOL VALERATE OR 17 B- ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE FREE
CY1107485T1 (en) 3-THYMOMYTHYPYRAZOLES AS PARASIDICIDES
CY1112614T1 (en) TREATMENT WITH TREATMENT FOR MULTIPLE SCLEROSIS
MX2015007753A (en) Vaccine composition for naive subjects.
CY1121187T1 (en) AN EXTRACT FROM INDIGO NATURALIS AND A PROCESS FOR MAKING HIM
CY1114468T1 (en) Roflumilasti for the treatment of pulmonary hypertension